ABSTRACT
Identification of a novel compound heterozygous of GNB5 in a patient with intellectual developmental disorder with cardiac arrhytmia (IDDCA), from non-consaguineous family. Three-dimensional modelling and in silico predictions suggest that GNB5 variants are causative of the phenotype, extending the number of IDDCA patients so far identified.
Subject(s)
Arrhythmias, Cardiac/complications , Arrhythmias, Cardiac/genetics , GTP-Binding Protein beta Subunits/genetics , Intellectual Disability/complications , Intellectual Disability/genetics , Mutation/genetics , Amino Acid Sequence , Child, Preschool , Evolution, Molecular , GTP-Binding Protein beta Subunits/chemistry , Heterozygote , Humans , Infant , Male , PedigreeABSTRACT
Understanding of BRCA1/2 interaction with the base excision repair (BER) pathway could improve therapy based on 'synthetic lethality', whose effectiveness is based on homologous recombination deficiency in cells lacking functional BRCA genes. However, poly (ADP-ribose) polymerase (PARP) inhibitors failed in some patients and for this reason we explored BER key enzyme expression. In this study, the expression of BER enzymes (redox factor 1/apurinic-apyrimidinic endonuclease 1 (REF1/APEX1), NTH endonuclease III-like 1 (NTHL1), 8-oxoguanine DNA glycosylase (OGG1), PARP1) and of the scaffold protein XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1) were investigated in familial (BRCA-related and not) and sporadic breast cancer cases. Furthermore, miR17 expression was measured because of its role in the epigenetic regulation of BRCA1. Gene expression was evaluated in BRCA1-mutated cell lines, SUM149PT and SUM1315MO2, and in a BRCA1-proficient triple-negative MDA-MB-231 cell line. A cohort of 27 familial and 16 sporadic breast cancer patients was then examined to confirm results obtained from the cell line model. APEX1/REF1 was found to be upregulated in familial BRCA-wild-type and sporadic cases, indicating this enzyme as a potential therapeutic target. Furthermore, XRCC1 was overexpressed in BRCAX patients; consequently, we suggest to test the effectiveness of inhibitors targeting two different BER components in preclinical studies. XRCC1, which is also involved in the non-homologous end-joining pathway, was found to be downregulated in BRCA2-related patients concurrently with no change in PARP1 expression. Interestingly, no difference in PARP1 and miR17 expression was found in BRCA-related and sporadic breast cancer cases. PARP1 and miR17 could therefore be further investigated as molecular biomarkers of 'BRCAness' phenotype, indicating patients which could really benefit from PARP inhibitor therapies.
Subject(s)
Biomarkers, Tumor/metabolism , DNA Repair , MicroRNAs/metabolism , Triple Negative Breast Neoplasms/metabolism , Adult , Aged , Animals , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Biomarkers, Tumor/genetics , Cell Line, Tumor , Computational Biology , DNA Glycosylases/genetics , DNA Glycosylases/metabolism , DNA Repair/genetics , DNA-(Apurinic or Apyrimidinic Site) Lyase/genetics , DNA-(Apurinic or Apyrimidinic Site) Lyase/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Databases, Genetic , Deoxyribonuclease (Pyrimidine Dimer)/genetics , Deoxyribonuclease (Pyrimidine Dimer)/metabolism , Female , Genetic Predisposition to Disease , HEK293 Cells , Humans , Mice , Middle Aged , Mutation , Phenotype , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/genetics , Poly(ADP-ribose) Polymerases/metabolism , Transfection , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/pathology , X-ray Repair Cross Complementing Protein 1ABSTRACT
This single-centre study investigated parameters that positively correlated with the success rate after islet allotransplantation in insulin-dependent diabetic (IDDM) patients. Twenty-one intrahepatic, fresh islet transplantations were performed in 20 IDDM patients (one patient had two transplants), after or simultaneous with kidney transplantation. The correlation between number and purity of transplanted islets and final outcome was investigated. One patient died of a cardiac arrest several hours after islet transplantation; this patient was not included in the follow-up analysis. Three patients (15%) experienced acute, irreversible, early failure of islet function, which was considered as a 'presumed rejection'. Nine patients (45%) achieved either complete insulin-independence (seven cases) or a reduction (> 50%) of exogenous insulin requirement (two cases), with sustained serum C-peptide secretion (0.89 +/- 0.04 nmol/l; duration: 21 +/- 7 months, range 2-58 months). Liver biopsy, performed 3 years after transplantation in one successful case, showed normal islets within the hepatic parenchyma. Eight cases (40%) did not show any metabolic effect of islet transplantation, with low serum C-peptide levels ('presumed function exhaustion'). Metabolic investigations performed in successful cases showed an early phase of insulin release after arginine, mild and reversible postprandial hyperglycaemia and normal HbA1c levels. Success of islet transplantation positively correlates with the number (p < 0.05) of the transplanted islets. Islet transplantation is a safe procedure, with 45% success rate, in terms of insulin-independence or relevant reductions of exogenous insulin requirement, although success can be transient.
Subject(s)
Diabetes Mellitus, Type 1/therapy , Insulin/metabolism , Islets of Langerhans Transplantation/physiology , Kidney Transplantation/physiology , Adult , Antilymphocyte Serum/administration & dosage , Azathioprine/administration & dosage , Blood Glucose/metabolism , Cyclosporine/administration & dosage , Female , Graft Survival , Humans , Immunosuppressive Agents/administration & dosage , Male , Prednisolone/administration & dosageSubject(s)
Diabetes Mellitus, Type 1/surgery , Diabetic Nephropathies/surgery , Islets of Langerhans Transplantation/pathology , Islets of Langerhans Transplantation/physiology , Islets of Langerhans/cytology , Kidney Transplantation , Adult , Blood Glucose/metabolism , C-Peptide/blood , Cell Separation/methods , Diabetes Mellitus, Type 1/blood , Female , Glycated Hemoglobin/analysis , Graft Rejection/epidemiology , Humans , Insulin/therapeutic use , Kidney Failure, Chronic/surgery , Male , Postoperative Care , Transplantation, Homologous , Treatment OutcomeSubject(s)
Islets of Langerhans/physiology , Adolescent , Adult , Cell Separation/methods , Collagenases , Female , Glucose/administration & dosage , Humans , In Vitro Techniques , Insulin/metabolism , Insulin Secretion , Islets of Langerhans/metabolism , Islets of Langerhans Transplantation , Male , Middle Aged , Multivariate Analysis , Pancreas/cytology , Perfusion , Retrospective Studies , Tissue DonorsABSTRACT
It has been shown that peripheral glucagon secreting cells (A-cells) are lost during most of the isolation procedures employed for pig islets. Loss of A-cells decreases intra-islet glucagon levels and cAMP levels in B-cells and might reduce glucose-induced insulin release. This study was designed to test this hypothesis, by evaluating the effects of culture of porcine islets with exogenous glucagon on insulin secretion and on insulin and cAMP content in islets. Islets were isolated from adult 2-year old Large White pigs using an automated method. The number of A-cells was calculated by immunostaining for glucagon in islets before and after isolation and a significant decrease in A-cells was observed. After an overnight culture, islets were cultured for 48 h in a standard medium (CMRL 1066, 10% foetal calf serum, 1% antibiotics, 1% glutamine) alone or in the presence of glucagon at two different concentrations (1.0 and 10.0 microM); exposure to glucagon was either continuous or alternated with periods of incubation in CMRL 1066 alone. After the 48-h culture in standard medium, the islet glucagon response to arginine was almost negligible and significantly lower than that observed in human islets.(ABSTRACT TRUNCATED AT 250 WORDS)